Genentech Mum On Roche Deal As Analysts Guess Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Third-quarter earnings call features grumbles over lack of transparency.
You may also be interested in...
Genentech’s Sigh Of Relief: RIBBON-1 Trial Supports Avastin Use In Breast Cancer
Third study to show progression-free survival in metastatic breast cancer puts the company closer to full approval, and data on new combinations could expand the market.
Genentech’s Sigh Of Relief: RIBBON-1 Trial Supports Avastin Use In Breast Cancer
Third study to show progression-free survival in metastatic breast cancer puts the company closer to full approval, and data on new combinations could expand the market.
Let The Negotiations Begin: Genentech Rejects Roche’s $44 Billion Bid
Genentech’s announcement that Roche’s $89 per share bid undervalues the biotech comes as little surprise. But how much is Roche willing to pay?